These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 21999727)

  • 1. Editorial: nitric oxide: implications for the etiology and treatment of central nervous system disorders.
    Di Giovanni G
    CNS Neurol Disord Drug Targets; 2011 Nov; 10(7):764-5. PubMed ID: 21999727
    [No Abstract]   [Full Text] [Related]  

  • 2. Structural modifications that alter the P-glycoprotein efflux properties of compounds.
    Hitchcock SA
    J Med Chem; 2012 Jun; 55(11):4877-95. PubMed ID: 22506484
    [No Abstract]   [Full Text] [Related]  

  • 3. [New drugs in neurology].
    Mattle HP
    Praxis (Bern 1994); 1999 Apr; 88(18):827-34. PubMed ID: 10409881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory watch: Challenges in drug development for central nervous system disorders: a European Medicines Agency perspective.
    Butlen-Ducuing F; Pétavy F; Guizzaro L; Zienowicz M; Haas M; Alteri E; Salmonson T; Corruble E
    Nat Rev Drug Discov; 2016 Nov; 15(12):813-814. PubMed ID: 27895328
    [No Abstract]   [Full Text] [Related]  

  • 5. Society for Neuroscience--38th Annual Meeting--Data for therapeutics for CNS diseases and disorders.
    Macauley D; Al-Shamahi A
    IDrugs; 2009 Jan; 12(1):17-9. PubMed ID: 19127499
    [No Abstract]   [Full Text] [Related]  

  • 6. Progress and promise of antisense oligonucleotide therapeutics for central nervous system diseases.
    Bishop KM
    Neuropharmacology; 2017 Jul; 120():56-62. PubMed ID: 27998711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain iNOS: current understanding and clinical implications.
    Licinio J; Prolo P; McCann SM; Wong ML
    Mol Med Today; 1999 May; 5(5):225-32. PubMed ID: 10322315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Trials in CNS--SMi's Seventh Annual Conference. 25-26 November 2008, London, UK.
    Sherwood D
    IDrugs; 2009 Feb; 12(2):84-6. PubMed ID: 19204879
    [No Abstract]   [Full Text] [Related]  

  • 9. Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents.
    Cole PE; Schwarz AJ; Schmidt ME
    Clin Pharmacol Ther; 2012 Feb; 91(2):315-20. PubMed ID: 22218072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of sex-related differences in central nervous system disorders for drug research and development.
    Butlen-Ducuing F; Balkowiec-Iskra E; Dalla C; Slattery DA; Ferretti MT; Kokras N; Balabanov P; De Vries C; Mellino S; Santuccione Chadha A
    Nat Rev Drug Discov; 2021 Dec; 20(12):881-882. PubMed ID: 34226696
    [No Abstract]   [Full Text] [Related]  

  • 11. Small molecules as central nervous system therapeutics: old challenges, new directions, and a philosophic divide.
    Banks WA; Greig NH
    Future Med Chem; 2019 Mar; 11(6):489-493. PubMed ID: 30912980
    [No Abstract]   [Full Text] [Related]  

  • 12. The therapeutic potential of sigma (σ) receptors for the treatment of central nervous system diseases: evaluation of the evidence.
    Banister SD; Kassiou M
    Curr Pharm Des; 2012; 18(7):884-901. PubMed ID: 22288410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial: Linkage of CNS and Immunology with Psychology: Searching for New Pharmacological Targets.
    Caraci F; Kamal MA
    CNS Neurol Disord Drug Targets; 2016; 15(4):378-80. PubMed ID: 27040760
    [No Abstract]   [Full Text] [Related]  

  • 14. Translational CNS medicines research.
    Palmer AM; Alavijeh MS
    Drug Discov Today; 2012 Oct; 17(19-20):1068-78. PubMed ID: 22580061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sphingosine-1-phosphate receptor therapies: Advances in clinical trials for CNS-related diseases.
    O'Sullivan S; Dev KK
    Neuropharmacology; 2017 Feb; 113(Pt B):597-607. PubMed ID: 27825807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges in the search for drugs to treat central nervous system disorders.
    Enna SJ; Williams M
    J Pharmacol Exp Ther; 2009 May; 329(2):404-11. PubMed ID: 19182069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting neuronal function for CNS drug discovery.
    Hempel CM; Werley CA; Dempsey GT; Gerber DJ
    Drug Discov Today Technol; 2017 Mar; 23():17-25. PubMed ID: 28647082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Role of nitric oxide in physiologic and pathologic function of the central nervous system].
    Tutka P; Kleinrok Z
    Postepy Hig Med Dosw; 1995; 49(2):189-99. PubMed ID: 8657626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Securing the future of drug discovery for central nervous system disorders.
    Andersen PH; Moscicki R; Sahakian B; Quirion R; Krishnan R; Race T; Phillips A;
    Nat Rev Drug Discov; 2014 Dec; 13(12):871-2. PubMed ID: 25435203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Academic Drug Discovery in the Quest for New CNS Therapeutics.
    Yokley BH; Hartman M; Slusher BS
    ACS Chem Neurosci; 2017 Mar; 8(3):429-431. PubMed ID: 28195461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.